We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 16 for:    crispr | cancer | China
Previous Study | Return to List | Next Study

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03545815
Recruitment Status : Unknown
Verified August 2020 by Han weidong, Chinese PLA General Hospital.
Recruitment status was:  Recruiting
First Posted : June 4, 2018
Last Update Posted : August 10, 2020
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital

Brief Summary:
Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, we use the technique of CRISPR-Cas9 to knocked out the PD-1 and TCR of chimeric antigen receptor (CAR) T cells to effect the immuno-microenvironment around tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Biological: anti-mesothelin CAR-T cells Phase 1

Detailed Description:
  1. To evaluate the feasibility and safety of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out chimeric antigen receptor (CAR) T cells in patients with mesothelin positive multiple solid tumors.
  2. To evaluate the duration of in vivo persistence of transferred CAR-T cells.
  3. To observe and measure anti-tumor responses for patients with detectable mesothelin positive tumor lesions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study to Evaluate Treatment of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Chimeric Antigen Receptor (CAR) T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
Actual Study Start Date : March 19, 2018
Estimated Primary Completion Date : October 30, 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: anti-mesothelin CAR-T cells

Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.

Patients receive anti-mesothelin-CAR T cells on day 0.

Biological: anti-mesothelin CAR-T cells
Cells will be infused on day 0.

Primary Outcome Measures :
  1. study of related adverse events [ Time Frame: 24 weeks ]
    Grade 3 signs/symptoms, toxicities and clinical

Secondary Outcome Measures :
  1. clinical responses to anti-mesothelin cell infusions [ Time Frame: 24 weeks ]
    Disease control rate(DCR)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed with mesothelin positive multiple solid tumors.
  2. Failure of at least one prior standard of care chemotherapy for advanced stage disease.
  3. Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria.
  4. Patients > 18 years of age.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
  6. Life expectancy > 12 weeks.
  7. Satisfactory organ and bone marrow function as defined by the following (of note, the minimal blood counts should be in the absence of transfusion or cytokine support):

    i. Absolute neutrophil count > 1,000/μl ii. Platelets >75,000/μl iii. Hemoglobin > 9 g/dL iv. Bilirubin < 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine < 1.5x the institutional normal upper limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5x the institutional normal upper limit viii. Cardiac ejection fraction of >55% as measured by resting echocardiogram, with no significant pericardial effusion.

  8. Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT < 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters.
  9. Ability to understand and the willingness to provide written informed consent.
  10. Male and Female subjects of reproductive potential agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) and abstain from other methods of conception during the study and for 6 months following the study cell infusion or proof of sterility.

Exclusion Criteria

  1. Sarcomatoid MPM histology which is known in the literature to not express mesothelin; biphasic MPM is also excluded.
  2. This refers to non-commercially approved investigational drugs different than those used in this protocol.Participated in any other trial in which receipt of an investigational study drug occurred within 28 days prior to enrollment and anticipated treatment with another investigational product while on study.
  3. Anticipated need for systemic chemotherapy within 2 weeks before apheresis and infusion of CART-meso cells.
  4. Active invasive cancer other than the one of the three cancers in this study. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded.CART-meso in mesothelin expressing cancers
  5. HIV, HCV, or HBV infections
  6. Active autoimmune disease (including but not limited to: systemic lupus erythromatosis, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks, with exception of thyroid replacement.
  7. Patients with ongoing or active infection.
  8. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (<10mg equivalent of prednisone) for chronic respiratory conditions.
  9. Patients requiring supplemental oxygen therapy.
  10. Prior therapy with gene modified cells.
  11. Previous experimental therapy with SS1 moiety, murine or chimeric antibodies (human and humanized antibodies are allowed).
  12. History of allergy to murine proteins
  13. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)
  14. Any clinically significant pericardial effusion; CHF (NY Heart Association Grade II-IV) or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist.
  15. Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches. An indwelling drainage device placed prior to enrollment is acceptable.
  16. Pregnant or breastfeeding women. Female study participants of reproductive potential must have a negative urine pregnancy test of enrollment. A serum pregnancy test will be performed within 2 weeks before infusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03545815

Layout table for location contacts
Contact: Wweidong Han, Dr. 86-10-13651392893 hanwdrsw@sina.com

Layout table for location information
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital Recruiting
Beijing, China, 100853
Contact: Weidong Han    86-10-13651392893    hanwdrsw@sina.com   
Sponsors and Collaborators
Chinese PLA General Hospital
Layout table for additonal information
Responsible Party: Han weidong, Director, Chinese PLA General Hospital
ClinicalTrials.gov Identifier: NCT03545815    
Other Study ID Numbers: CHN-PLAGH-BT-028
First Posted: June 4, 2018    Key Record Dates
Last Update Posted: August 10, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Han weidong, Chinese PLA General Hospital:
mesothelin, CRISPR-Cas9, PD-1, TCR
Additional relevant MeSH terms:
Layout table for MeSH terms